Neuroendocrine Tumor Treatment Market - Global Outlook and Forecast 2022-2028

March 2022 | 67 pages | ID: N1C49CEC42DDEN
Market Monitor Global

Abstracts

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

This report contains market size and forecasts of Neuroendocrine Tumor Treatment in Global, including the following market information:

Global Neuroendocrine Tumor Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Neuroendocrine Tumor Treatment market was valued at 1538.6 million in 2021 and is projected to reach US$ 2260 million by 2028, at a CAGR of 5.6% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Everolimus Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neuroendocrine Tumor Treatment include Exelixis, Inc., Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Hutchinson Medipharma Limited, Ispen, Novartis AG, Progenics Pharmaceuticals, Inc. and Tarveda Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neuroendocrine Tumor Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neuroendocrine Tumor Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Neuroendocrine Tumor Treatment Market Segment Percentages, by Type, 2021 (%)

• Everolimus
• Sunitinib
• Lu-Dotatate
• Lanreotide
• Octreotide

Global Neuroendocrine Tumor Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Neuroendocrine Tumor Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinic
• Others

Global Neuroendocrine Tumor Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Neuroendocrine Tumor Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neuroendocrine Tumor Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Neuroendocrine Tumor Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Exelixis, Inc.
• Advanced Accelerator Applications
• Dauntless Pharmaceuticals, Inc.
• Hutchinson Medipharma Limited
• Ispen
• Novartis AG
• Progenics Pharmaceuticals, Inc.
• Tarveda Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Neuroendocrine Tumor Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Neuroendocrine Tumor Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUROENDOCRINE TUMOR TREATMENT OVERALL MARKET SIZE

2.1 Global Neuroendocrine Tumor Treatment Market Size: 2021 VS 2028
2.2 Global Neuroendocrine Tumor Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Neuroendocrine Tumor Treatment Players in Global Market
3.2 Top Global Neuroendocrine Tumor Treatment Companies Ranked by Revenue
3.3 Global Neuroendocrine Tumor Treatment Revenue by Companies
3.4 Top 3 and Top 5 Neuroendocrine Tumor Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Neuroendocrine Tumor Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neuroendocrine Tumor Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Neuroendocrine Tumor Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Neuroendocrine Tumor Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Neuroendocrine Tumor Treatment Market Size Markets, 2021 & 2028
  4.1.2 Everolimus
  4.1.3 Sunitinib
  4.1.4 Lu-Dotatate
  4.1.5 Lanreotide
  4.1.6 Octreotide
4.2 By Type - Global Neuroendocrine Tumor Treatment Revenue & Forecasts
  4.2.1 By Type - Global Neuroendocrine Tumor Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Neuroendocrine Tumor Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Neuroendocrine Tumor Treatment Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Neuroendocrine Tumor Treatment Revenue & Forecasts
  5.2.1 By Application - Global Neuroendocrine Tumor Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Neuroendocrine Tumor Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neuroendocrine Tumor Treatment Market Size, 2021 & 2028
6.2 By Region - Global Neuroendocrine Tumor Treatment Revenue & Forecasts
  6.2.1 By Region - Global Neuroendocrine Tumor Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Neuroendocrine Tumor Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Neuroendocrine Tumor Treatment Revenue, 2017-2028
  6.3.2 US Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.3.3 Canada Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.3.4 Mexico Neuroendocrine Tumor Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Neuroendocrine Tumor Treatment Revenue, 2017-2028
  6.4.2 Germany Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.4.3 France Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.4.4 U.K. Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.4.5 Italy Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.4.6 Russia Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.4.8 Benelux Neuroendocrine Tumor Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Neuroendocrine Tumor Treatment Revenue, 2017-2028
  6.5.2 China Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.5.3 Japan Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.5.4 South Korea Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.5.6 India Neuroendocrine Tumor Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Neuroendocrine Tumor Treatment Revenue, 2017-2028
  6.6.2 Brazil Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.6.3 Argentina Neuroendocrine Tumor Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Neuroendocrine Tumor Treatment Revenue, 2017-2028
  6.7.2 Turkey Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.7.3 Israel Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Neuroendocrine Tumor Treatment Market Size, 2017-2028
  6.7.5 UAE Neuroendocrine Tumor Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Exelixis, Inc.
  7.1.1 Exelixis, Inc. Corporate Summary
  7.1.2 Exelixis, Inc. Business Overview
  7.1.3 Exelixis, Inc. Neuroendocrine Tumor Treatment Major Product Offerings
  7.1.4 Exelixis, Inc. Neuroendocrine Tumor Treatment Revenue in Global Market (2017-2022)
  7.1.5 Exelixis, Inc. Key News
7.2 Advanced Accelerator Applications
  7.2.1 Advanced Accelerator Applications Corporate Summary
  7.2.2 Advanced Accelerator Applications Business Overview
  7.2.3 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Major Product Offerings
  7.2.4 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Revenue in Global Market (2017-2022)
  7.2.5 Advanced Accelerator Applications Key News
7.3 Dauntless Pharmaceuticals, Inc.
  7.3.1 Dauntless Pharmaceuticals, Inc. Corporate Summary
  7.3.2 Dauntless Pharmaceuticals, Inc. Business Overview
  7.3.3 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Major Product Offerings
  7.3.4 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue in Global Market (2017-2022)
  7.3.5 Dauntless Pharmaceuticals, Inc. Key News
7.4 Hutchinson Medipharma Limited
  7.4.1 Hutchinson Medipharma Limited Corporate Summary
  7.4.2 Hutchinson Medipharma Limited Business Overview
  7.4.3 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Major Product Offerings
  7.4.4 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Revenue in Global Market (2017-2022)
  7.4.5 Hutchinson Medipharma Limited Key News
7.5 Ispen
  7.5.1 Ispen Corporate Summary
  7.5.2 Ispen Business Overview
  7.5.3 Ispen Neuroendocrine Tumor Treatment Major Product Offerings
  7.5.4 Ispen Neuroendocrine Tumor Treatment Revenue in Global Market (2017-2022)
  7.5.5 Ispen Key News
7.6 Novartis AG
  7.6.1 Novartis AG Corporate Summary
  7.6.2 Novartis AG Business Overview
  7.6.3 Novartis AG Neuroendocrine Tumor Treatment Major Product Offerings
  7.6.4 Novartis AG Neuroendocrine Tumor Treatment Revenue in Global Market (2017-2022)
  7.6.5 Novartis AG Key News
7.7 Progenics Pharmaceuticals, Inc.
  7.7.1 Progenics Pharmaceuticals, Inc. Corporate Summary
  7.7.2 Progenics Pharmaceuticals, Inc. Business Overview
  7.7.3 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Major Product Offerings
  7.7.4 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue in Global Market (2017-2022)
  7.7.5 Progenics Pharmaceuticals, Inc. Key News
7.8 Tarveda Therapeutics
  7.8.1 Tarveda Therapeutics Corporate Summary
  7.8.2 Tarveda Therapeutics Business Overview
  7.8.3 Tarveda Therapeutics Neuroendocrine Tumor Treatment Major Product Offerings
  7.8.4 Tarveda Therapeutics Neuroendocrine Tumor Treatment Revenue in Global Market (2017-2022)
  7.8.5 Tarveda Therapeutics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neuroendocrine Tumor Treatment Market Opportunities & Trends in Global Market
Table 2. Neuroendocrine Tumor Treatment Market Drivers in Global Market
Table 3. Neuroendocrine Tumor Treatment Market Restraints in Global Market
Table 4. Key Players of Neuroendocrine Tumor Treatment in Global Market
Table 5. Top Neuroendocrine Tumor Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Neuroendocrine Tumor Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Neuroendocrine Tumor Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Neuroendocrine Tumor Treatment Product Type
Table 9. List of Global Tier 1 Neuroendocrine Tumor Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neuroendocrine Tumor Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Neuroendocrine Tumor Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Neuroendocrine Tumor Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Neuroendocrine Tumor Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Neuroendocrine Tumor Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Neuroendocrine Tumor Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Neuroendocrine Tumor Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Exelixis, Inc. Corporate Summary
Table 31. Exelixis, Inc. Neuroendocrine Tumor Treatment Product Offerings
Table 32. Exelixis, Inc. Neuroendocrine Tumor Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Advanced Accelerator Applications Corporate Summary
Table 34. Advanced Accelerator Applications Neuroendocrine Tumor Treatment Product Offerings
Table 35. Advanced Accelerator Applications Neuroendocrine Tumor Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Dauntless Pharmaceuticals, Inc. Corporate Summary
Table 37. Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product Offerings
Table 38. Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Hutchinson Medipharma Limited Corporate Summary
Table 40. Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Product Offerings
Table 41. Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Ispen Corporate Summary
Table 43. Ispen Neuroendocrine Tumor Treatment Product Offerings
Table 44. Ispen Neuroendocrine Tumor Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Novartis AG Corporate Summary
Table 46. Novartis AG Neuroendocrine Tumor Treatment Product Offerings
Table 47. Novartis AG Neuroendocrine Tumor Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Progenics Pharmaceuticals, Inc. Corporate Summary
Table 49. Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product Offerings
Table 50. Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Tarveda Therapeutics Corporate Summary
Table 52. Tarveda Therapeutics Neuroendocrine Tumor Treatment Product Offerings
Table 53. Tarveda Therapeutics Neuroendocrine Tumor Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Neuroendocrine Tumor Treatment Segment by Type in 2021
Figure 2. Neuroendocrine Tumor Treatment Segment by Application in 2021
Figure 3. Global Neuroendocrine Tumor Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Neuroendocrine Tumor Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Neuroendocrine Tumor Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neuroendocrine Tumor Treatment Revenue in 2021
Figure 8. By Type - Global Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
Figure 12. US Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
Figure 24. China Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Neuroendocrine Tumor Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Neuroendocrine Tumor Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Exelixis, Inc. Neuroendocrine Tumor Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Advanced Accelerator Applications Neuroendocrine Tumor Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Ispen Neuroendocrine Tumor Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Novartis AG Neuroendocrine Tumor Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Tarveda Therapeutics Neuroendocrine Tumor Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)